Search - tctmd.com

Displaying 441 - 460 of 628

Sort: Relevancy | Date

Presentation NY Valves 2024

SAVR After TAVR: A Dangerous Epidemic?

Presenter: Shinichi Fukuhara

June 06, 2024

Presentation NY Valves 2024

Redo TAVR Through Embolized Evolut FX Valve

Presenter: Richard Tanner

June 06, 2024

Presentation NY Valves 2024

TAVR-in-TAVR for an Early Degenerated Bio-Prosthesis

Presenter: Vivek Patel

June 06, 2024

Presentation NY Valves 2024

What is the Status of Valve-in-Valve TAVR in a Bioprosthesis?

Presenter: Gilbert H. L. Tang

June 06, 2024

Presentation NY Valves 2024

Redo TAVR in a Young Patient With Congenital AV Disease

Presenter: Richard Tanner

June 06, 2024

Presentation NY Valves 2024

CT Planning With Redo TAV App Guiding Strategy to Prevent Coronary Obstruction for TAV-in-TAV Procedure

Presenter: Supawat Ratanapo

June 06, 2024

Presentation NY Valves 2024

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

Presenter: Ajit P. Yoganathan

June 06, 2024

Presentation NY Valves 2024

J-Valve

Presenter: Santiago Garcia

June 06, 2024

Presentation NY Valves 2024

Determinants of Intervention Type and All-Cause Mortality of TAVR and SAVR Patients Younger Than 75 Years in the Netherlands

Presenter: Nicolas M. Van Mieghem

June 06, 2024

Presentation NY Valves 2024

SAVR Will Have a Longer Lasting Durability Than TAVR

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

TAV-in-TAV With a 23mm SAPIEN3 Ultra Resilia in a Degenerated 23mm SAPIEN3 Valve

Presenter: Supawat Ratanapo

June 06, 2024

Presentation NY Valves 2024

TAVR Will Have a Longer Lasting Durability Than SAVR

Presenter: Michael J. Reardon

June 06, 2024

Presentation NY Valves 2024

JenaValve

Presenter: Raj Makkar

June 06, 2024

Presentation NY Valves 2024

Metanalysis of Clinical and Hemodynamic Differences in Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus

Presenter: Errol Christopher Moras

June 06, 2024

Presentation NY Valves 2024

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Presenter: Mark Lebehn

June 06, 2024

Presentation NY Valves 2024

Cases 1/2 : TAVR at 8 Years and SVD at 2 Years

Presenter: Guillaume Bonnet

June 06, 2024

Presentation NY Valves 2024

SIEGEL TAVR: A Revolutionary Ultra-Low Profile Aortic Valve Based Upon Rhenium Superalloys (Mirus)

Presenter: Pradeep K. Yadav

June 06, 2024

Presentation NY Valves 2024

Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: A Propensity-Matched Analysis of Gender-Based Outcomes

Presenter: Danial Ahmad

June 06, 2024

Presentation NY Valves 2024

Echo-Derived Gradients Increase at 30 Days in Most Patients After Balloon-Expandable TAVR Irrespective of Valve Type and Valve Size

Presenter: Spencer Ng

June 06, 2024

Presentation NY Valves 2024

First TAVR-in-TAVR for a Dedicated Self-Expandable Device for Pure Aortic Regurgitation

Presenter: Jonathan Curio

June 06, 2024

Advertisement

SAVR After TAVR: A Dangerous Epidemic?

Redo TAVR Through Embolized Evolut FX Valve

TAVR-in-TAVR for an Early Degenerated Bio-Prosthesis

What is the Status of Valve-in-Valve TAVR in a Bioprosthesis?

Redo TAVR in a Young Patient With Congenital AV Disease

CT Planning With Redo TAV App Guiding Strategy to Prevent Coronary Obstruction for TAV-in-TAV Procedure

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

J-Valve

Determinants of Intervention Type and All-Cause Mortality of TAVR and SAVR Patients Younger Than 75 Years in the Netherlands

SAVR Will Have a Longer Lasting Durability Than TAVR

TAV-in-TAV With a 23mm SAPIEN3 Ultra Resilia in a Degenerated 23mm SAPIEN3 Valve

TAVR Will Have a Longer Lasting Durability Than SAVR

JenaValve

Metanalysis of Clinical and Hemodynamic Differences in Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Cases 1/2 : TAVR at 8 Years and SVD at 2 Years

SIEGEL TAVR: A Revolutionary Ultra-Low Profile Aortic Valve Based Upon Rhenium Superalloys (Mirus)

Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: A Propensity-Matched Analysis of Gender-Based Outcomes

Echo-Derived Gradients Increase at 30 Days in Most Patients After Balloon-Expandable TAVR Irrespective of Valve Type and Valve Size

First TAVR-in-TAVR for a Dedicated Self-Expandable Device for Pure Aortic Regurgitation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content